Gene therapy: Progress and predictions

Proceedings of the Royal Society B: Biological Sciences

Volumn 282, Issue 1821, 2015, Pages

  Collins, Mary ^a,c   Thrasher, Adrian ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Evolutionary medicine; Gene therapy; Personalized medicine

Indexed keywords

BIOENGINEERING; CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; GENE; GENE TRANSFER; GENETIC MARKER; INFECTIOUS DISEASE; MEDICINE;

BONE MARROW TRANSPLANTATION; COMMUNICABLE DISEASES; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HEMOPHILIA B; HUMAN; NEOPLASMS; PROCEDURES; RETINAL DEGENERATION; TRENDS; VIRUS;

BONE MARROW TRANSPLANTATION; COMMUNICABLE DISEASES; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEMOPHILIA B; HUMANS; NEOPLASMS; RETINAL DEGENERATION; VIRUSES;

EID: 84951938836     PISSN: 09628452     EISSN: 14712954     Source Type: Journal    
DOI: 10.1098/rspb.2014.3003     Document Type: Review

References (89)

1. Fox MS, Littlefield JW. 1971 Reservations concerning gene therapy. Science 173, 195. (doi:10.1126/ science.173.3993.195)
2. Lander ES et al. 2001 Initial sequencing and analysis of the human genome. Nature 409, 860-921. (doi:10.1038/35057062)
3. OMIM 2013 OMIM statistics for January 7, 2013. See http://www.ncbi.nlm.nih.gov/Omim/mimstats.html.
4. Journal of Gene Medicine 2015 Gene therapy clinical trials worldwide. See http://www.wiley.com/legacy/ wileychi/genmed/clinical.
5. Stayte S, Vissel B. 2014 Advances in nondopaminergic treatments for Parkinson's disease. Front. Neurosci. 8, 113.
6. Joseph A et al. 2008 Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. J. Virol. 82, 3078-3089. (doi:10.1128/ JVI.01812-07)
7. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. 2012 Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481, 81-84. (doi:10. 1038/nature10660)
8. Tebas P et al. 2014 Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl. J. Med. 370, 901-910. (doi:10.1056/ NEJMoa1300662)
9. Collins MK, Cerundolo V. 2004 Gene therapy meets vaccine development. Trends Biotechnol. 22, 623-626. (doi:10.1016/j.tibtech.2004. 10.006)
10. Jelkmann W, Lundby C. 2011 Blood doping and its detection. Blood 118, 2395-2404. (doi:10.1182/ blood-2011-02-303271)
11. Varmus HE, Vogt PK, Bishop JM. 1973 Integration of deoxyribonucleic acid specific for Rous sarcoma virus after infection of permissive and nonpermissive hosts. Proc. Natl Acad. Sci. USA 70, 3067-3071. (doi:10.1073/pnas.70.11. 3067)
12. Tabin CJ, Hoffmann JW, Goff SP, Weinberg RA. 1982 Adaptation of a retrovirus as a eucaryotic vector transmitting the herpes simplex virus thymidine kinase gene. Mol. Cell. Biol. 2, 426-436. (doi:10. 1128/MCB.2.4.426)
13. Mann R, Mulligan RC, Baltimore D. 1983 Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33, 153-159. (doi:10.1016/0092- 8674(83)90344-6)
14. Danos O, Mulligan RC. 1988 Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl Acad. Sci. USA 85, 6460-6464. (doi:10.1073/pnas. 85.17.6460)
15. Miller AD, Garcia JV, von Suhr N, Lynch CM, Wilson C, Eiden MV. 1991 Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol. 65, 2220-2224.
16. Williams DA, Lemischka IR, Nathan DG, Mulligan RC. 1984 Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature 310, 476-480. (doi:10.1038/310476a0)
17. Hock RA, Miller AD. 1986 Retrovirus-mediated transfer and expression of drug resistance genes in human haematopoietic progenitor cells. Nature 320, 275-277. (doi:10.1038/320275a0)
18. Rosenberg SA et al. 1990 Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl. J. Med. 323, 570-578. (doi:10.1056/NEJM199008303230904)
19. Roe T, Reynolds TC, Yu G, Brown PO. 1993 Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12, 2099-2108.
20. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. 1996 In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267. (doi:10.1126/science.272.5259.263)
21. Ambrose Z, Aiken C. 2014 HIV-1 uncoating: connection to nuclear entry and regulation by host proteins. Virology 454-455, 371-379. (doi:10. 1016/j.virol.2014.02.004)
22. Leboulch P, Huang GM, Humphries RK, Oh YH, Eaves CJ, Tuan DY, London IM. 1994 Mutagenesis of retroviral vectors transducing human beta-globin gene and beta-globin locus control region derivatives results in stable transmission of an active transcriptional structure. EMBO J. 13, 3065-3076.
23. May C, Rivella S, Chadburn A, Sadelain M. 2002 Successful treatment of murine b-thalassemia intermedia by transfer of the human beta-globin gene. Blood 99, 1902-1908. (doi:10.1182/blood. V99.6.1902)
24. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, Masurier C. 2010 Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Therapy 21, 704-712. (doi:10.1089/hum.2009.182)
25. Berns KI, Pinkerton TC, Thomas GF, Hoggan MD. 1975 Detection of adeno-associated virus (AAV)- specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology 68, 556-560. (doi:10.1016/0042-6822(75)90298-6)
26. Kotin RM et al. 1990 Site-specific integration by adeno-associated virus. Proc. Natl Acad. Sci. USA 87, 2211-2215. (doi:10.1073/pnas.87.6.2211)
27. Hermonat PL, Muzyczka N. 1984 Use of adenoassociated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc. Natl Acad. Sci. USA 81, 6466-6470. (doi:10.1073/pnas. 81.20.6466)
28. McLaughlin SK, Collis P, Hermonat PL, Muzyczka N. 1988 Adeno-associated virus general transduction vectors: analysis of proviral structures. J. Virol. 62, 1963-1973.
29. Xiao X, Li J, Samulski RJ. 1998 Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224-2232.
30. Flotte TR et al. 1993 Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc. Natl Acad. Sci. USA 90, 10 613-10 617. (doi:10.1073/ pnas.90.22.10613)
31. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O'Malley KL, During MJ. 1994 Long-term gene expression and phenotypic correction using adenoassociated virus vectors in the mammalian brain. Nat. Genet. 8, 148-154. (doi:10.1038/ng1094-148)
32. Vincent-Lacaze N, Snyder RO, Gluzman R, Bohl D, Lagarde C, Danos O. 1999 Structure of adenoassociated virus vector DNA following transduction of the skeletal muscle. J. Virol. 73, 1949-1955.
33. Chandler RJ et al. 2015 Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J. Clin. Invest. 125, 870-880. (doi:10.1172/JCI79213)
34. Ferrari FK, Samulski T, Shenk T, Samulski RJ. 1996 Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adenoassociated virus vectors. J. Virol. 70, 3227-3234.
35. McCarty DM, Monahan PE, Samulski RJ. 2001 Selfcomplementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Therapy 8, 1248-1254. (doi:10.1038/sj.gt.3301514)
36. Khan IF, Hirata RK, Russell DW. 2011 AAV-mediated gene targeting methods for human cells. Nat. Protocols 6, 482-501. (doi:10.1038/nprot.2011.301)
37. Urnov FD et al. 2005 Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435, 646-651. (doi:10.1038/ nature03556)
38. Arnould S et al. 2007 Engineered I-CreI derivatives cleaving sequences from the human XPC gene can induce highly efficient gene correction in mammalian cells. J. Mol. Biol. 371, 49-65. (doi:10. 1016/j.jmb.2007.04.079)
39. Miller JC et al. 2011 A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143-148. (doi:10.1038/nbt.1755)
40. Genovese P et al. 2014 Targeted genome editing in human repopulating haematopoietic stem cells. Nature 510, 235-240. (doi:10.1038/ nature13420)
41. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. 2013 RNA-guided human genome engineering via Cas9. Science 339, 823-826. (doi:10.1126/science.1232033)
42. Hu W et al. 2014 RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc. Natl Acad. Sci. USA 111, 11 461-11 466. (doi:10.1073/pnas.1405186111)
43. Ye L et al. 2014 Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc. Natl Acad. Sci. USA 111, 9591-9596. (doi:10.1073/pnas.1407473111)
44. Schwank G et al. 2013 Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13, 653-658. (doi:10.1016/j.stem.2013.11.002)
45. Yin H et al. 2014 Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551-553. (doi:10. 1038/nbt.2884)
46. Aiuti A et al. 2002 Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410-2413. (doi:10. 1126/science.1070104)
47. Aiuti A et al. 2009 Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl. J. Med. 360, 447-458. (doi:10. 1056/NEJMoa0805817)
48. Gaspar HB et al. 2011 Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci. Transl. Med. 3, 97ra80. (doi:10.1126/ scitranslmed.3002716)
49. Candotti F et al. 2012 Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 120, 3635-3646. (doi:10.1182/blood-2012-02-400937)
50. Hacein-Bey-Abina S et al. 2002 Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl. J. Med. 346, 1185-1193. (doi:10.1056/ NEJMoa012616)
51. Hacein-Bey-Abina S et al. 2008 Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142. (doi:10.1172/JCI35700)
52. Howe SJ et al. 2008 Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143-3150. (doi:10. 1172/JCI35798)
53. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A. 1991 Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65, 737-752. (doi:10.1016/0092-8674(91)90382-9)
54. Hacein-Bey-Abina S et al. 2014 A modified gammaretrovirus vector for X-linked severe combined immunodeficiency. N Engl. J. Med. 371, 1407-1417. (doi:10.1056/NEJMoa1404588)
55. Stein S et al. 2010 Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198-204. (doi:10.1038/nm.2088)
56. Boztug K et al. 2010 Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl. J. Med. 363, 1918-1927. (doi:10.1056/NEJMoa1003548)
57. Aiuti A et al. 2013 Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151. (doi:10.1126/ science.1233151)
58. Cartier N et al. 2009 Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823. (doi:10.1126/science.1171242)
59. Biffi A et al. 2013 Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158. (doi:10. 1126/science.1233158)
60. Cavazzana-Calvo M et al. 2010 Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia. Nature 467, 318-322. (doi:10.1038/nature09328)
61. Cesana D, Sgualdino J, Rudilosso L, Merella S, Naldini L, Montini E. 2012 Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J. Clin. Invest. 122, 1667-1676. (doi:10.1172/JCI62189)
62. Knight S et al. 2012 Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing. J. Virol. 86, 9088-9095. (doi:10. 1128/JVI.00485-12)
63. Bessant DA, Ali RR, Bhattacharya SS. 2001 Molecular genetics and prospects for therapy of the inherited retinal dystrophies. Curr. Opin. Genet. Dev. 11, 307-316. (doi:10.1016/S0959-437X(00)00195-7)
64. Bainbridge JW et al. 2008 Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl. J. Med. 358, 2231-2239. (doi:10.1056/ NEJMoa0802268)
65. Maguire AM et al. 2008 Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl. J. Med. 358, 2240-2248. (doi:10.1056/ NEJMoa0802315)
66. Jacobson SG et al. 2012 Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch. Ophthalmol. 130, 9-24. (doi:10.1001/archophthalmol.2011.298)
67. MacLaren RE et al. 2014 Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 383, 1129-1137. (doi:10.1016/S0140-6736(13)62117-0)
68. Kay MA et al. 2000 Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24, 257-261. (doi:10.1038/73464)
69. Manno CS et al. 2006 Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347. (doi:10.1038/nm1358)
70. Nathwani AC et al. 2011 Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl. J. Med. 365, 2357-2365. (doi:10.1056/ NEJMoa1108046)
71. Nathwani AC et al. 2014 Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl. J. Med. 371, 1994-2004. (doi:10.1056/ NEJMoa1407309)
72. Friedmann T. 1992 Gene therapy of cancer through restoration of tumor-suppressor functions? Cancer 70(Suppl. 6), 1810-1817. (doi:10.1002/1097- 0142(19920915)70:4+,1810::AIDCNCR2820701624.3.0. CO;2-3)
73. Piccart-Gebhart MJ et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl. J. Med. 353, 1659-1672. (doi:10. 1056/NEJMoa052306)
74. Brahmer JR et al. 2012 Safety and activity of anti- PD-L1 antibody in patients with advanced cancer. N Engl. J. Med. 366, 2455-2465. (doi:10.1056/ NEJMoa1200694)
75. Topalian SL et al. 2012 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl. J. Med. 366, 2443-2454. (doi:10.1056/ NEJMoa1200690)
76. Galon J et al. 2006 Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964. (doi:10.1126/science.1129139)
77. Maus MV, Grupp SA, Porter DL, June CH. 2014 Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123, 2625-2635. (doi:10.1182/blood-2013-11-492231)
78. Green M, Ishino M, Loewenstein PM. 1989 Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 58, 215-223. (doi:10.1016/0092-8674(89)90417-0)
79. Venkatesh LK, Arens MQ, Subramanian T, Chinnadurai G. 1990 Selective induction of toxicity to human cells expressing human immunodeficiency virus type 1 Tat by a conditionally cytotoxic adenovirus vector. Proc. Natl Acad. Sci. USA 87, 8746-8750. (doi:10.1073/pnas. 87.22.8746)
80. Hutter G et al. 2009 Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl. J. Med. 360, 692-698. (doi:10.1056/ NEJMoa0802905)
81. Balazs AB, Bloom JD, Hong CM, Rao DS, Baltimore D. 2013 Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat. Biotechnol. 31, 647-652. (doi:10. 1038/nbt.2618)
82. Limberis MP et al. 2013 Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. Sci. Transl. Med. 5, 187ra72. (doi:10.1126/scitranslmed. 3006299)
83. Gossen M, Bujard H. 1992 Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl Acad. Sci. USA 89, 5547-5551. (doi:10.1073/pnas.89.12. 5547)
84. Palfi S et al. 2014 Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, openlabel, phase 1/2 trial. Lancet 383, 1138-1146. (doi:10.1016/S0140-6736(13)61939-X)
85. Taimeh Z, Loughran J, Birks EJ, Bolli R. 2013 Vascular endothelial growth factor in heart failure. Nat. Rev. Cardiol. 10, 519-530. (doi:10.1038/ nrcardio.2013.94)
86. Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, Hajjar RJ. 2014 Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circul. Res. 114, 101-108. (doi:10.1161/CIRCRESAHA. 113.302421)
87. Moss RB et al. 2007 Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum. Gene Therapy 18, 726-732. (doi:10.1089/hum.2007.022)
88. Adair JE et al. 2014 Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. J. Clin. Invest. 124, 4082-4092. (doi:10.1172/JCI76739)
89. Zwaka TP. 2009 Use of genetically modified stem cells in experimental gene therapies. See http:// stemcells.nih.gov/info/Regenerative_medicine/ pages/2006chapter4.aspx.